» Articles » PMID: 6983044

Glucose Utilization of Cerebral Gliomas Measured by [18F] Fluorodeoxyglucose and Positron Emission Tomography

Overview
Journal Neurology
Specialty Neurology
Date 1982 Dec 1
PMID 6983044
Citations 184
Authors
Affiliations
Soon will be listed here.
Abstract

Positron emission tomography was used to measure local cerebral glucose utilization by the 1-[18F]fluoro-2-deoxy-D-glucose technique in 23 patients with cerebral gliomas. All 10 high-grade (III and IV) astrocytomas demonstrated a region of high activity with a glucose consumption of 7.4 +/- 3.5 (SD) mg/100 gm per minute. The 13 low-grade (I and II) gliomas had a glucose metabolic rate of 4.0 +/- 1.8 mg/100 gm per minute, with no distinctly visible hot spot. Thus, we found a correlation between rate of glycolysis and malignancy in primary cerebral tumors. Cerebral cortical glucose utilization was often depressed in areas adjacent to or neurally connected to the tumor site, and there was focal irregular delta wave EEG activity in these areas.

Citing Articles

Imaging Role in Diagnosis, Prognosis, and Treatment Response Prediction Associated with High-grade Glioma.

Heidari M, Shokrani P J Med Signals Sens. 2024; 14:7.

PMID: 38993200 PMC: 11111132. DOI: 10.4103/jmss.jmss_30_22.


Recent Update on PET/CT Radiotracers for Imaging Cerebral Glioma.

Kim D, Lee S, Hwang H, Kim S, Yun M Nucl Med Mol Imaging. 2024; 58(4):237-245.

PMID: 38932755 PMC: 11196511. DOI: 10.1007/s13139-024-00847-4.


The Role of Multimodal Imaging in Differentiating Vasogenic from Infiltrative Edema: A Systematic Review.

Hasanzadeh A, Moghaddam H, Shakiba M, Jalali A, Firouznia K Indian J Radiol Imaging. 2023; 33(4):514-521.

PMID: 37811185 PMC: 10556327. DOI: 10.1055/s-0043-1772466.


Clinical application of real-time PET/CT guided targeted retroperitoneal masses biopsy in diagnosing malignant tumors.

Li X, Zhang W BMC Cancer. 2023; 23(1):829.

PMID: 37670264 PMC: 10481464. DOI: 10.1186/s12885-023-11334-y.


HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer.

Wang M, Chen Y, Xu H, Zhan J, Suo D, Wang J Cancer Sci. 2022; 114(4):1365-1377.

PMID: 36519789 PMC: 10067396. DOI: 10.1111/cas.15692.